Patents by Inventor Peter Richardson

Peter Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10596263
    Abstract: A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Gossett Augustus Campbell, Helen Richardson, Peter A. Williams
  • Patent number: 10498794
    Abstract: Embodiments of the present invention are directed to a social entertainment platform that supports live social video streaming and messaging. One common use for this social entertainment platform is to allow audience members to watch and interact with a person playing an electronic game. The social entertainment platform allows a streamer to stream live (in substantially real-time) on a network(s), such as the Internet, for a live audience to view and to respond to the live entertainment. The social entertainment platform includes several unique areas, including a real-time broadcasting component, a real-time messaging component, and an integrated user interface (UI) component, that make the social entertainment platform advantageous to use over traditional platforms.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 3, 2019
    Assignee: Caffeine, Inc.
    Inventors: Ben Keighran, Sam Roberts, Justin Henzie, Doug Richardson, George Leontiev, Peter Sankauskas, Nicolas Artman
  • Publication number: 20190344240
    Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.
    Type: Application
    Filed: May 28, 2019
    Publication date: November 14, 2019
    Inventors: Peter Fitzgerald, John Lamont, Ivan McConnell, Elouard Benchikh, Deepesh Upadhyay, Ciaran Richardson
  • Publication number: 20190247820
    Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 15, 2019
    Inventors: Peter Fitzgerald, John Lamont, Ivan McConnell, Elouard Benchikh, Deepesh Upadhyay, Ciaran Richardson
  • Publication number: 20190212332
    Abstract: The disclosure provides methods and apparatus for high speed and sterile sorting of heterogeneous populations of cells to isolate homogenous populations. In embodiments, the disclosure provides a micropore array and collection tray situated within a sterile, closed cartridge.
    Type: Application
    Filed: September 19, 2017
    Publication date: July 11, 2019
    Inventors: Ivan DIMOV, Nathaniel FERNHOFF, Irving WEISSMAN, Charles Kwok Fai CHAN, Everett MEYER, Peter Lincoln WANG, Bruce RICHARDSON
  • Publication number: 20190167580
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Publication number: 20190154672
    Abstract: The present invention relates to a multiplexing system comprising a support substrate having immobilised thereto one or more of the following proteins, fragments thereof or a binding molecule, wherein the binding molecule binds specifically to one of the following proteins: E-FABP, B-FABP, IL-FABP, I-FABP, M-FABP, A-FABP, H-FABP, L-FABP or T-FABP. Another aspect is directed to a method for characterising the pattern of FABP antigens existing within a biological sample to reveal information useful in the diagnosis or disease or injury.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 23, 2019
    Applicants: Randox Laboratories Ltd., Randox Teoranta
    Inventors: Ivan McConnell, Peter Fitzgerald, John Lamont, Ciaran Richardson
  • Patent number: 10224717
    Abstract: Embodiments of the present invention produce and define a relationship between local voltage and power measurements at a node of an electrical network and system conditions on a remote branch of the network. These local measurements are used to determine an optimal voltage set point at the node that, if realized by a reactive power resource, would affect the flow of reactive power or line current at one or more particular remote branches of the power system in a manner captured by the derived relationship. The change in reactive power required to obtain this voltage set point is also calculated based on local measurements.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 5, 2019
    Assignee: Univ. College Dublin, Nat'l. Univ. of Ireland
    Inventors: Conor Murphy, Andrew Keane, Peter Richardson
  • Publication number: 20190000861
    Abstract: The invention relates to a combination of CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide and an immune checkpoint inhibitor, and the use of the same in the treatment of tumours and/or cancers.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 3, 2019
    Inventor: Peter Richardson
  • Publication number: 20180360786
    Abstract: The present invention relates to (R)-carbidopa and pharmaceutical compositions thereof, and to a combined preparation of (R)-carbidopa and a steroid, and to the use of the same in the treatment or prevention of medical conditions such as pain, inflammatory diseases, immune or autoimmune disorders and tumour growth.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicant: PROXIMAGEN GROUP LIMITED
    Inventors: Martyn PRITCHARD, Peter RICHARDSON
  • Publication number: 20180360808
    Abstract: This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicant: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Martyn PRITCHARD, Peter RICHARDSON
  • Publication number: 20180263992
    Abstract: Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting EGFR signalling, and inhibiting MyD88-dependent TLR/IL-R1 signalling, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of EGFR signalling, and an inhibitor of MyD88-dependent TLR/IL-R1 signalling.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 20, 2018
    Inventors: Peter RICHARDSON, Richard MEAD, Laura FERRAIUOLO, Kenneth Patrick MULVANY
  • Publication number: 20180185453
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 5, 2018
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20180104223
    Abstract: (3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.
    Type: Application
    Filed: April 22, 2016
    Publication date: April 19, 2018
    Applicant: PROXIMAGEN LIMITED
    Inventors: Isabel GONZALEZ, Martyn PRITCHARD, Peter RICHARDSON
  • Patent number: 9943571
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: April 17, 2018
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20180078563
    Abstract: The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 22, 2018
    Applicant: PROXIMAGEN LIMITED
    Inventors: Peter RICHARDSON, Jacqueline Mary WALLING, Claudio FESTUCCIA
  • Publication number: 20170304404
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: July 3, 2017
    Publication date: October 26, 2017
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Patent number: 9365651
    Abstract: The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: June 14, 2016
    Assignee: Novartis AG
    Inventors: Jerome Feige, David Glass, Shinji Hatakeyama, Brian Peter Richardson, Estelle Trifilieff
  • Publication number: 20160099566
    Abstract: Embodiments of the present invention produce and define a relationship between local voltage and power measurements at a node of an electrical network and system conditions on a remote branch of the network. These local measurements are used to determine an optimal voltage set point at the node that, if realised by a reactive power resource, would affect the flow of reactive power or line current at one or more particular remote branches of the power system in a manner captured by the derived relationship. The change in reactive power required to obtain this voltage set point is also calculated based on local measurements.
    Type: Application
    Filed: December 14, 2015
    Publication date: April 7, 2016
    Inventors: Conor MURPHY, Andrew KEANE, Peter RICHARDSON
  • Publication number: 20150283213
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: May 22, 2015
    Publication date: October 8, 2015
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino